NEW YORK – Shift Bioscience, a UK-based startup, said it has raised $16 million in seed funding.
BGF led the round, joined by F-Prime Capital, Kindred Capital, and Jonathan Milner. In a statement, the firm said it would use the funding to continue development of its artificial intelligence-based cell simulation platform as well as an IP portfolio for genes identified by the platform. The firm is using it to understand how activation of different genes can change cells involved in different aging-related processes and to identify gene targets for the potential treatment of age-related illnesses.
"Our technology is addressing the current limitations of cellular reprogramming for treatment of age-related illnesses," Shift CEO Daniel Ives said in a statement. "This additional funding will allow us to accelerate the development of our platform and bring cell rejuvenation therapeutics closer towards clinical trial."
Shift's cell simulation platform combines generative AI with its epigenetics-based biological aging clock to predict which sets of genes are most likely to "rejuvenate" specific cells.
The firm added that it has now raised a total of $18 million.